This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio
Key takeaways
- (MRVI) is a Top penny Stock in the Top Investors Portfolio Neha Gupta Mon, June 8, 2026 at 12:59 AM GMT+7 2 min read MRVI Maravai Life Sciences Holdings Inc.
- Increased focus on cost structure and operational efficiency helped the company achieve robust revenue growth and meaningful EBITDA expansion in the first quarter.
- Net loss in the quarter shrank to $6.4 million, compared with $52.9 million in the same quarter last year.
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio Neha Gupta Mon, June 8, 2026 at 12:59 AM GMT+7 2 min read MRVI Maravai Life Sciences Holdings Inc. (NASDAQ:MRVI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 7, Maravai Life Sciences Holdings Inc. (NASDAQ:MRVI) affirmed a strong start to the year, driven by strong demand in the core Tri Link base business and strength in the higher-margin portfolio.
Increased focus on cost structure and operational efficiency helped the company achieve robust revenue growth and meaningful EBITDA expansion in the first quarter. Revenue in the first quarter was up 40.5% to $65.8 million, driven by a 65.1% increase in TriLink revenue at $47.5 million. Maravai LifeSciences Holdings benefited from high-volume CleanCap orders for commercial-phase COVID vaccine programs.
Net loss in the quarter shrank to $6.4 million, compared with $52.9 million in the same quarter last year. The company also bounced back to adjusted EBITDA of $20.3 million, compared with a loss of $10.5 million in the same quarter last year. For the full year, the company expects revenue to range from $205 million to $215 million, up from its previous guidance of $200 million to $210 million.